We are contacting you today to inform you of a revised policy available in our HPP Policy Bulletin Library. Effective December 1, 2022, HPP will be implementing a revised drug policy: DR.006.C Complement Inhibitors: Eculizumab (Soliris®) & Ravulizumab (Ultomiris®).

You can access this policy by visiting our policy bulletin library at www.hpplans.com/PolicyBulletins.

As a reminder, HPP’s medical policy bulletins define medical necessity criteria and coverage positions on topics such as medical services, procedures, DME, therapies, etc., while our claim payment policy bulletins provide reimbursement rules and billing guidelines necessary to ensure timely and appropriate payment.

Thank you for your support in providing the highest quality of care to our members.